notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title 難治性ループス腎炎
Subtitle 特集 〈Clinical Science〉 全身性エリテマトーデス : 診断と治療の進歩
Authors 久保かなえ
Authors (kana)
Organization 東京都健康長寿医療センター膠原病・リウマチ科
Journal 炎症と免疫
Volume 28
Number 3
Page 218-224
Year/Month 2020 / 5
Article 報告
Publisher 先端医学社
Abstract ループス腎炎は, 免疫学的背景や腎病理組織所見においてheterogeneousな疾患であり, 臨床像のみならず治療反応性や腎予後にも影響を及ぼし, 治療選択において層別化を要する. 活動性増殖性ループス腎炎の場合, 標準治療である高用量ステロイドとシクロホスファミド(CY)またはミコフェノール酸モフェチル(MMF)の併用による寛解導入療法と, 低用量ステロイドとMMFまたはアザチオプリン(AZA)の併用による寛解維持療法で治療反応性が得られ寛解を維持できる率は十分でなく, 生命予後, 腎予後に加えて疾患関連および治療関連ダメージ蓄積予防をも考慮した新たな治療戦略が望まれる.
Practice 基礎医学・関連科学
Keywords ループス腎炎, 生物学的製剤, ミコフェノール酸モフェチル
  • 全文ダウンロード： 従量制、基本料金制の方共に935円(税込) です。
download全文ダウンロード(7.13MB)

参考文献

  • 1) Weening JJ et al : The classification of glomeru-lonephritis in systemic lupus erythematosus revisited. Kidney Int 65 : 521-30, 2004
  • 2) Bajema IM et al : Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis : clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93 : 789-796, 2018
    pubmed
  • 3) Hiramatsu N et al : Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology(Oxford) 47 : 702-7, 2008
    pubmed
  • 4) Yokoyama H et al ; Kanazawa Study Group for Renal Diseases and Hypertension : The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 66 : 2382-8, 2004
  • 5) Yang J et al : Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus 24 : 1468-78, 2015
残りの49件を表示する
  • 6) Rijnink EC et al : Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. Clin J Am Soc Nephrol 12 : 734-743, 2017
    pubmed
  • 7) Austin HA et al : Predicting renal outcomes in severe lupus nephritis : contributions of clinical and histologic data. Kidney Int 45 : 544-50, 1994
    pubmed
  • 8) Contreras G et al : Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14 : 890-5, 2005
    pubmed
  • 9) Hsieh C et al : Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res(Hoboken) 63 : 865-74, 2011
    pubmed
  • 10) Wu LH et al : Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predic-tions. Kidney Int 83 : 715-23, 2013
  • 11) Austin HA et al : Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314 : 614-9, 1986
    pubmed
  • 12) Appel GB et al : Aspreva Lupus Management Study Group : Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20 : 1103-12, 2009
  • 13) Weng M-Y et al : The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 29 : 771-5, 2010
    pubmed
  • 14) Houssiau FA et al : Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 : 2121-31, 2002
  • 15) Houssiau FA et al ; MAINTAIN Nephritis Trial Group : Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis : results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69 : 2083-9, 2010
    pubmed
  • 16) Dooley MA et al ; ALMS Group : Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 : 1886-95, 2011
    pubmed
  • 17) Tektonidou MG et al : Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015 : A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol 68 : 1432-41, 2016
    pubmed
  • 18) Yang J et al : Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus 24 : 1468-78, 2015
  • 19) Tamirou F et al : MAINTAIN Nephritis Trial Group : Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75 : 526-31, 2016
    pubmed
  • 20) Bao H et al : Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19 : 2001-10, 2008
  • 21) Liu Z et al : Multitarget therapy for induction treatment of lupus nephritis : a randomized trial. Ann Intern Med 162 : 18-26, 2015
    pubmed
  • 22) Zhang H et al : Multitarget Therapy for Mainte-nance Treatment of Lupus Nephritis. J Am Soc Nephrol 28 : 3671-3678, 2017
  • 23) Yap DYH et al : Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. J Rheumatol 44 : 1375-1383, 2017
    pubmed
  • 24) Pakchotanon R et al : Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal dis-ease in lupus nephritis. Lupus 27 : 468-474, 2018
  • 25) Chen YE et al ; Collaborative Study Group : Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3 : 46-53, 2008
    pubmed
  • 26) Petri M et al : Predictors of organ damage in systemic lupus erythematosus : the Hopkins Lupus Cohort. Arthritis Rheum 64 : 4021-8, 2012
    pubmed
  • 27) Bruce IN et al : Factors associated with damage accrual in patients with systemic lupus erythe-matosus : results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 74 : 1706-13, 2015
  • 28) Van Staa TP et al : Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 : 993-1000, 2000
    pubmed
  • 29) Ruiz-Arruza I et al : Glucocorticoids and irre-versible damage in patients with systemic lupus erythematosus. Rheumatology(Oxford) 53 : 1470-6, 2014
  • 30) Rovin BH et al ; AURA-LV Study Group : A randomized, controlled double-blind study com-paring the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95 : 219-231, 2019
  • 31) Furie R et al : OP0253 : A phase iii randomised, double-blind, placebo-controlled study to evalu-ate the efficacy and safety of abatacept or pla-cebo on standard of care in patients with active class iii or iv lupus nephritis. Ann Rheum Dis 77(Suppl 2), 2018
  • 32) Furie R et al : Efficacy and safety of abatacept in lupus nephritis : a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66 : 379-89, 2014
    pubmed
  • 33) Merrill JT et al : Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus : the randomized, double-blind, phase II/III systemic lupus erythematosus eval-uation of rituximab trial. Arthritis Rheum 62 : 222-33, 2010
  • 34) Rovin BH et al ; LUNAR Investigator Group : Efficacy and safety of rituximab in patients with active proliferative lupus nephritis : the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 : 1215-26, 2012
    pubmed
  • 35) Furie R et al : A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis [abstract 939]. Arthritis Rheumatol 71(suppl 10), 2019
  • 36) Navarra SV et al ; BLISS-52 Study Group : Effi-cacy and safety of belimumab in patients with active systemic lupus erythematosus : a ran-domised, placebo-controlled, phase 3 trial. Lan-cet 377 : 721-31, 2011
  • 37) Furie R et al ; BLISS-76 Study Group : A phase III, randomized, placebo-controlled study of beli-mumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with sys-temic lupus erythematosus. Arthritis Rheum 63 : 3918-30, 2011
  • 38) Oon S et al : Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belim-umab in systemic lupus erythematosus. Ann Rheum Dis 78 : 629-633, 2019
  • 39) Zhang F et al : A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77 : 355-363, 2018
  • 40) Dooley MA et al ; BLISS-52 and-76 Study Groups : Effect of belimumab treatment on renal outcomes : results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22 : 63-72, 2013
    pubmed
  • 41) Fanouriakis A et al : Low disease activity-irre-spective of serologic status at baseline-associ-ated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab : A real-life observational study. Semin Arthritis Rheum 48 : 467-474, 2018
  • 42) Urowitz MB et al : Organ damage in patients treated with belimumab versus standard of care : a propensity score-matched comparative analysis. Ann Rheum Dis 78 : 372-379, 2019
    pubmed
  • 43) Yokogawa N et al : Effects of Hydroxychloro-quine in Patients With Cutaneous Lupus Ery-thematosus : A Multicenter, Double-Blind, Ran-domized, Parallel-Group Trial. Arthritis Rheu-matol 69 : 791-799, 2017
  • 44) Shinjo SK et al : Antimalarial treatment may have a time-dependent effect on lupus sur-vival : data from a multinational Latin American inception cohort. Arthritis Rheum 62 : 855-62, 2010
  • 45) Canadian Hydroxychloroquine Study Group : A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324 : 150-4, 1991
  • 46) Fessler BJ et al : Systemic lupus erythematosus in three ethnic groups : XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52 : 1473-80, 2005
    pubmed
  • 47) Pons-Estel GJ et al : Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis : LXV, data from a multi-ethnic US cohort. Arthritis Rheum 61 : 830-9, 2009
  • 48) Miyagawa I et al : Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. Int J Rheum Dis 22 : 434-442, 2019
    pubmed
  • 49) Hanaoka H et al : Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Back-ground Treatment in Japanese Patients with Systemic Lupus Erythematosus. Intern Med 58 : 1257-1262, 2019
  • 50) Furie R et al ; CD1013 Study Investigators : Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheu-matol 69 : 376-386, 2017
  • 51) Furie R et al : A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients With Moderate to Severe Systemic Lupus Erythematosus. Pre-sented at : ACR 2019 Annual Meeting ; Novem-ber 8-13, 2019. Abstract ID : 1763
  • 52) van Vollenhoven RF et al : Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythemato-sus : results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392 : 1330-1339, 2018
  • 53) Furie R et al ; CD1013 Study Investigators. Ani-frolumab, an Anti-Interferon-α Receptor Mono-clonal Antibody, in Moderate-to-Severe Sys-temic Lupus Erythematosus. Arthritis Rheuma-tol 69 : 376-386, 2017
  • 54) Mathian A et al : Ultrasensitive serum inter-feron-α quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis 78 : 1669-1676, 2019
はじめての方へ
個人／法人会員登録のご案内